Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MAO-B Occupancy in Depressed Patients

NCT04841798

Major Depressive Disorder Treatment Resistant Depression

COMPLETED NA

Characterizing Dopamine Receptor Binding in Treatment Resistant Depression

NCT03537794

Treatment Resistant Depression

NOT_YET_RECRUITING

Neuro MRI Biomarkers for Treatment Navigation in Depression

NCT05701267

Depressive Disorder, Major

COMPLETED

PET Biomarkers in Treatment Resistant Depression

NCT01031810

Major Depressive Disorder

TERMINATED PHASE4

PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)

NCT04582916

Depression

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will receive a PET and MRI scan before and after treatment with phenelzine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phenelzine treatment

Subjects will undergo a PET and MRI scan before and after the treatment.

Group Type EXPERIMENTAL

phenelzine treatment

Intervention Type OTHER

Subjects will have a PET and MRI scan before and after treatment with phenelzine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phenelzine treatment

Subjects will have a PET and MRI scan before and after treatment with phenelzine.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-80 years of age
* good physical health
* Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)
* DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation
* greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
* history of non-response to several different antidepressant classes

Exclusion Criteria

* herbal, drug or medication use (that affect CNS function)
* suicide attempts
* drug or medication use within eight weeks (+5 half lives of medication)
* history of substance abuse or any neurotoxin use
* history of psychotic symptoms
* history of central nervous system (CNS) medical illness
* current substance abuse
* test positive on pregnancy test (for women)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No